We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Analysts Predict Robust Growth for Stem Cells and Regenerative Medicine

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The promise of stem cells and regenerative medicine discoveries and their potential to transform the treatment of disease, continues to drive biological research and technology development in the life sciences.

The fact that analysts predict that a market based on stem cell therapies could grow anywhere from $10-30 billion by 2010 makes it vital to gain a better understanding of how this science will advance the future of healthcare.

Considering this need, the Strategic Research Institute will bring together global thought leaders from academic and industrial research for two days of focused scientific discussion around emerging discoveries in stem cells and regenerative medicine.

The conference, scheduled for October 16-17th in Pittsburgh, will explore developments in: discovery cells, discovery enabling materials, pre-clinical development, clinical development, new technologies, commercialization & investment opportunities and regulatory issues.

Presenting companies and institutions include: Advanced Cell Technology, Arteriocyte, Avlar BioVentures, Celgene, Cellerant Therapeutics, Center for Biologics Evaluation and Research/US-FDA, Eli Lilly, Fred Hutchinson Cancer Research Center, Geron, Intercytex, McGowan Institute for Regenerative Medicine, Novocell, Pfizer, Pittsburgh Lifesciences Greenhouse, Pittsburgh Tissue Engineering Initiative, Plasticell, Proteus Venture Partners, Q Therapeutics, Reeve-Irvine Research Center, Rodman & Renshaw, Stem Cell Therapeutics Corp., The Biologics Consulting Group and the University of Wisconsin at Madison.

Early bird pricing ends Friday September 1, 2006, so people interested in attending are encouraged to register early.

Companies interested in sponsoring or exhibiting at the meeting should contact Hank Woji at 719-290-8836 or hwoji@srinstitute.com.

To receive the full agenda in PDF, please contact Seth Fritts of Strategic Research Institute at sfritts@srinstitute.com or 212-967-0095, x256. Visitor can also view the agenda and speakers online.